Vaxcyte said Monday that its experimental pneumococcal vaccine, VAX-31, met all of its prespecified primary goals in OPUS-1, a pivotal Phase 3 trial in U.S. adults. The company reported topline results that have not yet been peer-reviewed or evaluated by the Food and Drug Administration. The vaccine is designed to protect against 31 strains of Streptococcus pneumoniae.

Pneumococcal bacteria can cause pneumonia, meningitis and bloodstream infections, and older adults are particularly at risk, Reuters (opens in new tab) reported. In the trial, 3,572 pneumococcal-naive adults aged 50 and older were randomly assigned to receive a single dose of VAX-31, Pfizer’s Prevnar 20 (PCV20) or Merck’s Capvaxive (PCV21). In a separate group of 475 adults aged 18 to 49, participants were randomly assigned 3 to 1 to receive VAX-31 or Prevnar 20, which served as the safety comparator. In total, 4,047 people were dosed at about 30 U.S. sites, the company said.

According to Vaxcyte, all 28 serotypes that VAX-31 shares with one or both rival vaccines met the trial’s noninferiority standard, meaning its immune responses were not meaningfully weaker. Responses to the three serotypes found only in VAX-31, and to the related serotype 20B, met a stricter superiority standard. In head-to-head comparisons with each rival, VAX-31 met the main noninferiority threshold for all 20 serotypes it shares with PCV20 and for 17 of 19 shared with PCV21. Serotypes 3 and 12F missed that threshold against PCV21 but met a looser historical one, the company said.

The vaccine was well tolerated, with a safety profile similar to the two licensed vaccines, Vaxcyte said. Reuters (opens in new tab) reported that there were no serious adverse events considered related to the vaccines. Vaxcyte shares rose 57% in morning trading, according to Reuters (opens in new tab).

Vaxcyte expects results from two more adult Phase 3 trials, OPUS-2 and OPUS-3, in the first half of 2027. It plans to file a Biologics License Application with the FDA in the first half of 2028, after a manufacturing consistency study, the company said. “Given current U.S. epidemiology, with the serotypes unique to PCV21 accounting for a larger share of adult disease, we expect the comparison of VAX-31 to PCV21 to be a particular focus of FDA review,” said James Wassil, Vaxcyte’s chief scientific officer and chief operating officer.